[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0103908A3 - Novel infulenza virus vaccine composition - Google Patents

Novel infulenza virus vaccine composition

Info

Publication number
HUP0103908A3
HUP0103908A3 HU0103908A HUP0103908A HUP0103908A3 HU P0103908 A3 HUP0103908 A3 HU P0103908A3 HU 0103908 A HU0103908 A HU 0103908A HU P0103908 A HUP0103908 A HU P0103908A HU P0103908 A3 HUP0103908 A3 HU P0103908A3
Authority
HU
Hungary
Prior art keywords
infulenza
novel
vaccine composition
virus vaccine
virus
Prior art date
Application number
HU0103908A
Other languages
English (en)
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3515932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0103908(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of HUP0103908A2 publication Critical patent/HUP0103908A2/hu
Publication of HUP0103908A3 publication Critical patent/HUP0103908A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0103908A 1998-09-15 1999-09-14 Novel infulenza virus vaccine composition HUP0103908A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0155598A AT408615B (de) 1998-09-15 1998-09-15 Neue influenzavirus-impfstoffzusammensetzung
PCT/AT1999/000223 WO2000015251A2 (de) 1998-09-15 1999-09-14 Influenzavirus-impfstoffzusammensetzung

Publications (2)

Publication Number Publication Date
HUP0103908A2 HUP0103908A2 (hu) 2002-02-28
HUP0103908A3 true HUP0103908A3 (en) 2003-10-28

Family

ID=3515932

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103908A HUP0103908A3 (en) 1998-09-15 1999-09-14 Novel infulenza virus vaccine composition

Country Status (12)

Country Link
US (1) US6372223B1 (hu)
EP (1) EP1113816B1 (hu)
JP (1) JP2003523310A (hu)
AT (2) AT408615B (hu)
AU (1) AU763210B2 (hu)
DE (1) DE59913046D1 (hu)
DK (1) DK1113816T3 (hu)
ES (1) ES2257072T3 (hu)
HK (1) HK1038507A1 (hu)
HU (1) HUP0103908A3 (hu)
NO (1) NO20011282L (hu)
WO (1) WO2000015251A2 (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
DE60139026D1 (de) * 2000-09-25 2009-07-30 Polymun Scient Immunbio Forsch Lebender influenza impfstoff und verfahren zu seiner herstellung
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
KR100597699B1 (ko) * 2003-01-30 2006-07-07 학교법인 포항공과대학교 면역원성이 증강된 ｄｎａ 백신 조성물
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7270990B2 (en) 2003-06-20 2007-09-18 Microbix Biosystems, Inc. Virus production
BRPI0417225A (pt) * 2003-12-05 2007-03-06 Becton Dickinson Co métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
BRPI0509493A (pt) * 2004-04-01 2007-09-11 Alza Corp aparelho e método para a liberação transdérmica de vacina da influenza
WO2005103235A1 (ja) * 2004-04-19 2005-11-03 Denka Seiken Co., Ltd. ウイルスの生産方法
DE602005024827D1 (de) 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
EP1807116B1 (en) 2004-11-03 2015-05-06 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
KR20160064249A (ko) * 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2007052055A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
JP2009514841A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
GB0522601D0 (en) * 2005-11-04 2005-12-14 Chiron Srl Adjuvanted influenza vaccines and kits
DE06808434T1 (de) 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
CA2628333C (en) * 2005-11-04 2014-01-28 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2054431B1 (en) 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
CA2677455A1 (en) * 2007-02-07 2008-08-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Recombinant antigens of human cytomegalovirus (hcmv)
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
NZ582595A (en) 2007-06-27 2012-07-27 Novartis Ag Low-additive influenza vaccines
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
CN102170902B (zh) * 2008-08-01 2015-07-15 伽玛疫苗有限公司 流感疫苗
CN102307590A (zh) 2009-02-10 2012-01-04 诺华有限公司 具有减少量的角鲨烯的流感疫苗
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2776874A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
US9107875B2 (en) 2009-11-18 2015-08-18 Auburn University Low antigen-dose immunization for maximizing T-helper cell 1 (Th1) immunity against a pathogen
BR112013000394B8 (pt) 2010-07-06 2022-01-18 Variation Biotechnologies Inc Composição imunogênica, uso da mesma e método para preparar a referida composição
WO2012032482A1 (en) 2010-09-07 2012-03-15 Novartis Ag Generic assays for detection of mammalian reovirus
FR2966044B1 (fr) * 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
CN103533923A (zh) 2011-01-13 2014-01-22 变异生物技术公司 囊泡及由其产生之制剂的制备方法
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2012211043B2 (en) 2011-01-27 2017-04-06 Gamma Vaccines Pty Limited Combination vaccines
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
CN105534969B (zh) 2012-03-23 2019-04-05 皮特尼制药股份有限公司 用于癌症治疗的激酶抑制剂
JP2015520175A (ja) 2012-06-05 2015-07-16 ジ・オーストラリアン・ナショナル・ユニバーシティー インターロイキン−４アンタゴニストを伴うワクチン接種
NZ631523A (en) 2012-08-06 2017-03-31 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP6502853B2 (ja) 2012-12-17 2019-04-17 ニューサウス イノベイションズ ピーティーワイ リミテッド ムチンが関与する疾患の処置
AU2013370932B2 (en) 2012-12-24 2019-02-21 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US10364277B2 (en) 2013-07-01 2019-07-30 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
US20150166255A1 (en) * 2013-12-12 2015-06-18 ASCLEMED USA, INC. dba EnovaChem Manufacturing Vitamin b-12 injection kit
ES2782428T3 (es) 2014-04-18 2020-09-15 Univ Auburn Formulaciones vacunales de partículas para la inducción de inmunidad innata y adaptativa
US10293044B2 (en) 2014-04-18 2019-05-21 Auburn University Particulate formulations for improving feed conversion rate in a subject
EP3273989B1 (en) 2015-03-26 2023-12-27 Gpn Vaccines Pty Ltd Streptococcal vaccine
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100287083B1 (ko) * 1992-05-23 2001-04-16 장 스테판느 B형 간염 표면 항원 및 다른 항원을 포함하는 조합 백신
EP2290053A1 (en) * 1994-11-10 2011-03-02 Baxter Healthcare S.A. Method for producing Influenza virus in protein-free cell culture medium
FR2754715B1 (fr) * 1996-10-18 1998-11-13 Seppic Sa Adjuvant, notamment sous forme d'une emulsion contenant un cation metallique trivalent et composition vaccinale le comprenant
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers

Also Published As

Publication number Publication date
EP1113816B1 (de) 2006-01-11
AU763210B2 (en) 2003-07-17
AU5720099A (en) 2000-04-03
NO20011282D0 (no) 2001-03-14
HK1038507A1 (en) 2002-03-22
NO20011282L (no) 2001-05-14
HUP0103908A2 (hu) 2002-02-28
WO2000015251A3 (de) 2000-08-24
DE59913046D1 (de) 2006-04-06
DK1113816T3 (da) 2006-04-03
JP2003523310A (ja) 2003-08-05
ATA155598A (de) 2001-06-15
ES2257072T3 (es) 2006-07-16
US6372223B1 (en) 2002-04-16
WO2000015251A2 (de) 2000-03-23
EP1113816A2 (de) 2001-07-11
AT408615B (de) 2002-01-25
ATE315404T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
HUP0103908A3 (en) Novel infulenza virus vaccine composition
GB2337755B (en) Virus vaccine
GB9806456D0 (en) Vaccine composition
HK1105581A1 (en) Vaccine composition
HUP0101047A3 (en) Combined vaccine compositions
GB9812613D0 (en) Vaccine
GB9910812D0 (en) Vaccine composition
GB0027072D0 (en) Vaccine
GB9801870D0 (en) Vaccine composition
GB9925432D0 (en) Virus preparation
GB9702990D0 (en) Virus vaccine
GB9929434D0 (en) Novel vaccine composition
GB9802879D0 (en) Vaccine composition
GB9806455D0 (en) Vaccine composition
GB9807805D0 (en) Vaccine
GB9906694D0 (en) Vaccine composition
GB9906696D0 (en) Vaccine composition
GB9925434D0 (en) Virus Preparation
GB9930459D0 (en) Vaccine compositions
GB9930456D0 (en) Vaccine compositions
GB9930455D0 (en) Vaccine compositions
GB9930460D0 (en) Vaccine compositions
GB9930461D0 (en) Vaccine compositions
GB9930457D0 (en) Vaccine compositions
GB9930458D0 (en) Vaccine compositions